Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1452-1458

  Christensson, Anders ^a   Savage, Caroline ^b   Sjoberg, Daniel D ^b   Cronin, Angel M ^b   Frank O'Brien, M ^b   Lowrance, William ^b   Nilsson, Peter M ^a   Vickers, Andrew J ^b   Russo, Paul ^b   Lilja, Hans ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cancer; chronic kidney disease; kidney cancer; renal function

Indexed keywords

CREATININE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CANCER; KIDNEY DYSFUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SEX DIFFERENCE; URINARY TRACT CANCER;

CANCER; CHRONIC KIDNEY DISEASE; KIDNEY CANCER; RENAL FUNCTION;

ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK;

EID: 84879939905     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28144     Document Type: Article

References (25)

1. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
3. Foley RN, Parfrey PS, Sarnak MJ,. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23.
4. Shlipak MG, Katz R, Kestenbaum B, et al. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009; 204: 298-303.
5. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-46.
6. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16: 3728-35.
7. Curtis J,. Cancer and patients with end-stage renal failure. Br Med J 1982; 284: 69-70.
8. Ishikawa I, Kovacs G,. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993; 22: 135-9.
9. Matas AJ, Simmons RL, Kjellstrand CM, et al. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 1: 883-6.
10. Cengiz K,. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33: 121-6.
11. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-31.
12. Jorgensen L, Heuch I, Jenssen T, et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol 2008; 19: 992-8.
13. Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20: 1341-50.
14. Weng P-H, Hung K-Y, Huang H-L, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 2011; 6: 1121-8.
15. Berglund G, Eriksson KF, Israelsson B, et al. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med 1996; 239: 489-97.
16. Manjer J, Kaaks R, Riboli E, et al. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmö Preventive Project. Eur J Cancer Prevent 2001; 10: 33-42.
17. Lilja H, Ulmert D, Björk T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 431-436.
18. Berglund G, Nilsson P, Eriksson KF, et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 2000; 247: 19-29.
19. Levey A, Stevens L, Schmid C, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Int Med 2009; 150: 604-12.
20. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. DuBois D, DuBois E,. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
22. Kidney disease outcome quality initiative: K/DOQI clinical practice guidelines for chronic disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39: S76-S92.
23. Yuyun M, Khaw K, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European prospective investigation into cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189-98.
24. Dou L, Cerini C, Brunet P, et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009.
25. Faure V, Cerini C, Paul P, et al. The uremic solute p-cresol decreases leukocyte transendothelial migration in vitro. Int Immunol 2006; 18: 1453-9.